Cristina Gasparetto

Dr. Gasparetto performs both laboratory and clinical research in the field of multiple myeloma. Her primary research interests are in developing immunotherapy approaches to treating multiple myeloma particularly in conjunction with hematopoietic stem cell transplantation. Ongoing laboratory research projects include the development of dendritic cell vaccines and antibody therapies. Clinical studies include a recently approved trial involving vaccination with autologous dendritic cells pulsed with idiotypic protein following high dose chemotherapy and autologous peripheral blood stem cells transplant. Upcoming trials include novel antibody therapies for multiple myeloma. Dr. Gasparetto is also an investigator on several other clinical trials for myeloma including non-myeloablative allogeneic transplantation, high dose sequential chemotherapy and autologous peripheral blood stem cell transplantation and transplantation of partially HLA matched unrelated cord blood.

Current Appointments & Affiliations

Professor of Medicine · 2018 - Present Medicine, Hematologic Malignancies and Cellular Therapy, Medicine

Member of the Duke Cancer Institute · 1993 - Present Duke Cancer Institute, Institutes and Centers

Recent Publications

Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference.

Journal Article Am J Hematol · April 21, 2026 The rapid expansion of therapeutic options for multiple myeloma (MM) has created uncertainty regarding optimal sequencing and clinical application. To address gaps in evidence, the 2025 Bridging the Gaps Consensus Conference convened 16 US MM experts who r ... Full text Link to item Cite

Sociodemographic factors and timing of allogeneic hematopoietic stem cell transplantation in myeloproliferative neoplasms.

Journal Article Bone Marrow Transplant · April 12, 2026 Full text Link to item Cite

Impact of donor age on cognitive recovery in allogenic hematopoietic stem cell transplant patients with mild cognitive impairment.

Journal Article Bone Marrow Transplant · April 4, 2026 Full text Link to item Cite

View All Publications

Recent Grants

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation MajesTEC-4

Clinical TrialPrincipal Investigator · Awarded by National Marrow Donor Program · 2025 - 2030

Celgene: CA057-001 - A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480, BORTEZOMIB AND DEXAMETHASONE (480Vd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYE

Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2024 - 2029

A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma

Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2024 - 2029

View All Grants

Education

Sapienza University of Rome (Italy) · 1986 M.D.